IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0416514
(2001-11-20)
|
우선권정보 |
JP-0355393 (2000-11-22) |
국제출원번호 |
PCT/JP01/10128
(2003-05-22)
|
§371/§102 date |
20030522
(20030522)
|
국제공개번호 |
WO02/42284
(2002-05-30)
|
발명자
/ 주소 |
- Takeuchi, Tsutomu
- Takayanagi, Hiroaki
- Kobayashi, Seiki
- Osa, Yumiko
- Suzuki, Yumiko
- Sato, Yoko
- Sakaguchi, Masakazu
- Miyata, Yoshiyuki
|
출원인 / 주소 |
- Pola Chemical Industries, Inc.
|
대리인 / 주소 |
Oblon, Spivak, McClelland, Maier &
|
인용정보 |
피인용 횟수 :
2 인용 특허 :
1 |
초록
▼
Dibenzosuberanyl piperazine derivatives represented by the following formula (I): wherein R represents an aliphatic hydrocarbon group, which may contain one or more heteroatom-containing substituent groups and may preferably contain 2 to 30 carbon atoms, and physiologically acceptable salts thereof;
Dibenzosuberanyl piperazine derivatives represented by the following formula (I): wherein R represents an aliphatic hydrocarbon group, which may contain one or more heteroatom-containing substituent groups and may preferably contain 2 to 30 carbon atoms, and physiologically acceptable salts thereof; and medicinal compositions containing these dibenzosuberanyl piperazine derivatives and/or physiologically acceptable salts thereof.These compounds show effectiveness in allowing resistance-acquired causes of diseases to restore sensitivity to drug, that is, a resistance overcoming effect.
대표청구항
▼
1. A dibenzosuberanyl piperazine compound represented by the following formula (I): wherein R is an aliphatic hydrocarbon group containing i) one or more double bonds and/or triple bonds and ii) and a hydroxyl group; and wherein said aliphatic hydrocarbon group may contain one or more heteroatom-con
1. A dibenzosuberanyl piperazine compound represented by the following formula (I): wherein R is an aliphatic hydrocarbon group containing i) one or more double bonds and/or triple bonds and ii) and a hydroxyl group; and wherein said aliphatic hydrocarbon group may contain one or more heteroatom-containing substituent groups, or a physiologically acceptable salt thereof. 2. The compound or the physiologically acceptable salt thereof as defined in claim 1, wherein each heteroatom forming R in the formula (I) is an oxygen atom.3. The compound or the physiologically acceptable salt thereof as defined in claim 1 or 2, wherein R in the formula (I) is a Cr2-30 aliphatic hydrocarbon group which may contain one or more substituent groups each of which is selected from a hydroxyl group, a C1-4 acyl group or a C1-9 acyloxy group.4. The compound or the physiologically acceptable salt thereof as defined in claim 1 or 2, wherein R in the formula (I) is a C2-30 unsaturated aliphatic hydrocarbon group, which contains one or more double and/or triple bonds and may contain one or more substituent groups each of which is selected from a hydroxyl group, a C1-9 acyl group or a C1-4 acyloxy group.5. The compound or the physiologically acceptable salt thereof as defined in claim 1, wherein said compound represented by the formula (I) is a compound represented by the following formula (II): wherein R1 represents a hydrogen atom or a C1-4 alkyl group which may contain one or more hydroxyl groups, C1-4 acyl groups or C1-4 acyloxy groups; and R2 represents a C2-30 aliphatic hydrocarbon group which may contain one or more C1-4 acyl groups, C1-4 acyloxy groups and/or hydroxyl groups. 6. The compound or the physiologically acceptable salt as defined in claim 5, wherein R1 in the formula (II) represents a hydrogen atom or a C1-4 alkyl group which may contain one or more hydroxyl groups, C1-4 acyl groups or C1-4 acyloxy groups; and R2 represents a C2-30 unsaturated aliphatic hydrocarbon group which contains one or more double and/or triple bonds and may contain one or more C1-4 acyl groups, C1-4 acyloxy groups and/or hydroxyl groups.7. The compound or the physiologically acceptable salt thereof as defined in claim 5, wherein in the formula (II), R1 represents a hydrogen atom or a C1-4 alkyl group which may contain one or more hydroxyl groups; and R2 represents a C2-10 unsaturated aliphatic hydrocarbon group which contains one or two double and/or triple bonds and may contain one or more hydroxyl groups and/or C1-4 acyloxy groups.8. The compound or the physiologically acceptable salt thereof as defined in claim 1, wherein said compound represented by the formula (I) is a compound selected from the group consisting of the following compounds:1-dibenzosuberanyl-4-(4-hydroxydecan-9-en-1-yl)piperazine, 1-dibenzosuberanyl-4-(2-hydroxy-7-octenyl)piperazine, 1-dibenzosuberanyl-4-(2-hydroxy-5-hexenyl)piperazine, 1-dibenzosuberanyl-4-(2-hydroxy-3-butenyl)piperazine, 1-dibenzosuberanyl-4-(1-hydroxybutan-3-en-2-yl)piperazine, 1-dibenzosuberanyl-4-(4-hydroxy-2-butynyl)-piperazine, 1-dibenzosuberanyl-4-(4-acetoxy-2-butynyl)piperazine, and 1-dibenzosuberanyl-4-(2-hydroxydecanyl)piperazine. 9. A medicinal composition, comprising:one or more compounds or salts selected from the group consisting of a compound and a physiologically acceptable salt thereof as defined in claim 1. 10. A method for overcoming drug resistance of a hazardous microorganism, which comprises:administering an effective amount of one or more compounds or salts selected from the group consisting of compounds and physiologically acceptable salts thereof as defined in claim 1 to a subject in need thereof. 11. The method as defined in claim 10, wherein said hazardous microorganism is a plasmodium.12. The method of claim 10, wherein said hazardous microorganism is methicillin-resistant Staphylococcus aureus, vancomycin-resistance Euterococci, resistant tubercle bacillus, resistant Escherichia coli, resistant plasmodium or resistant Leishmania. 13. The method of claim 10, further comprising:administering a chemotherapeutic agent. 14. The compound of claim 1 or the physiologically acceptable salt thereof, which does not exhibit calcium antagonism, antidepressant effect or hypnotic effect.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.